ScripARCH Venture Partners raised its largest venture capital fund yet, the $1.85bn ARCH Venture Fund XI, which it plans to invest in a range of biotechnology opportunities, including drug developers focus
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. China Grand Alliance With eTheRNA Follo